Rh factor testing: Difference between revisions

Revision as of 14:15, 11 April 2019

Latest revision as of 21:53, 15 June 2025

(34 intermediate revisions by 20 users not shown)

Line 1:

{{short description|Blood test}}

'''Rh factor testing''', also known as Rhesus factor testing, is the procedure of determining the rhesusRhesus D status of an individual (see [[Rh blood group system]]).<ref>{{Cite web|url=https://www.babycenter.com/0_blood-test-for-rh-status-and-antibody-screen_1480.bc|archive-url=https://web.archive.org/web/20070911115522/http://www.babycenter.com/0_blood-test-for-rh-status-and-antibody-screen_1480.bc|url-status=usurped|archive-date=September 11, 2007|title=Blood test for Rh status and antibody screen|last=|first=|date=2019-03-07|website=BabyCenter|archive-url=|archive-date=|dead-url=|access-date=2019-03-07}}</ref><ref name=":0">{{Cite web|url=https://www.mayoclinic.org/tests-procedures/rh-factor/about/pac-20394960|title=Rh factor blood test - Mayo Clinic|website=www.mayoclinic.org|access-date=2019-04-08}}</ref>.

== Background ==

Rhesus factor testing utilises theutilizes [[genotyping]] technique to detect the presence of the [[RHD (gene)|RhD gene]]<ref name=":1">{{Cite journal|last=Flegel|first=Willy A.|date=April 2007|title=The genetics of the Rhesus blood group system|url=https://www.ncbi.nlm.nih.gov/pubmed/19204754|journal=Blood Transfusion = Trasfusione Del Sangue|volume=5|issue=2|pages=50–57|doi=10.2450/2007.0011-07|issn=1723-2007|pmc=PMC2535884|pmid=19204754|via=}}</ref>. By checking the existence of the RhD gene in the individual’sindividual's [[genome]], the presence of rhesusRhesus D (RhD) [[Antigen|antigensantigen]]s can be inferred. Individuals with a positive RhD status hashave RhD antigens expressed on the [[cell membrane]] of their [[Redred blood cell|red blood cells]]s, whereas Rhesus D antigens are absent for individuals with a negative RhD status<ref name=":2">{{Cite web|url=https://transfusion.com.au/blood_basics/blood_groups/inheritance_patterns|title=transfusion.com.au|website=transfusion.com.au|language=en|access-date=2019-04-08}}</ref>.

Rhesus factor testing is usually conductedperformed on pregnant women to determine the RhD blood group of the mother and the foetusfetus. By confirming the RhD status of both mother and foetusfetus, precautions can be made, if necessary, to prevent any medical conditionscomplications caused by rhesusRhesus incompatibility.<ref name=":0" />

=== Rhesus factor ===

The entire [[Rh blood group system]] involves multiple antigens and genes<ref name=":1" />. For Rh factor testing, however, only the rhesusRhesus factor which referscorrelated to the RhD antigen specifically is assayed<ref name=":1" />. The RhD gene that codes for the RhD antigen is located on [[chromosome 1]]. This chromosome contains gene instructions for making proteins in the body.<ref>{{Cite nameweb |title="Chromosome 1:2" MedlinePlus Genetics |url=https:/>/medlineplus.gov/genetics/chromosome/1/ |access-date=2024-04-07 |website=medlineplus.gov |language=en}}</ref> RhD is a dominant gene, meaning that as long as at least one RhD gene is inherited from eithera single parent, the RhD antigen is expressed<ref name=":2" />. Vice versa, if no RhD gene is inherited from either parent, no RhD antigen is produced.

== Extraction of test samples ==

=== '''Non-invasive extraction ==='''

[[Blood plasma]] is commonly used as test samples for verifying the maternal RhD status. Blood plasma can also be used for determining the foetal RhD status if the mother is RhD- as maternal blood plasma contains maternal [[DNA]] and trace amounts of foetal DNA<ref>{{Cite journal|last=Dovč-Drnovšek|first=Tadeja|last2=Klemenc|first2=Polona|last3=Toplak|first3=Nataša|last4=Blejec|first4=Tanja|last5=Bricl|first5=Irena|last6=Rožman|first6=Primož|date=Feb 2013|title=Reliable Determination of Fetal RhD Status by RHD Genotyping from Maternal Plasma|url=https://www.ncbi.nlm.nih.gov/pubmed/23637648|journal=Transfusion Medicine and Hemotherapy: Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|volume=40|issue=1|pages=37–43|doi=10.1159/000345682|issn=1660-3796|pmc=PMC3636019|pmid=23637648|via=}}</ref>. Blood samples can be obtained through [[venipuncture]] of the mother. Since plasma and other components of blood have different densities, [[centrifugation]] of blood samples with added [[anticoagulant]] (such as [[Ethylenediaminetetraacetic acid|EDTA]]) can segregate blood contents into multiples layers<ref>{{Cite journal|last=Dagur|first=Pradeep K.|last2=McCoy|first2=J. Philip|date=2015-07-01|title=Collection, Storage, and Preparation of Human Blood Cells|url=https://www.ncbi.nlm.nih.gov/pubmed/26132177|journal=Current Protocols in Cytometry|volume=73|pages=5.1.1–16|doi=10.1002/0471142956.cy0501s73|issn=1934-9300|pmc=PMC4524540|pmid=26132177|via=}}</ref>. Blood plasma can then be isolated from the other components for rhesus factor testing. The method of extracting foetal DNA from maternal blood plasma is considered to be a type of non-invasive [[prenatal testing]]<ref>{{Cite web|url=https://www.bbts.org.uk/blog/noninvasive_prenatal_testing_for_fetal_rhesus-d_status_-_putting_the_/|title=BBTS {{!}} Non-invasive prenatal testing for fetal rhesus-D status - putting the {{!}}|website=www.bbts.org.uk|access-date=2019-04-09}}</ref>.

[[Blood plasma]] is commonly used as test samples for verifying the maternal RhD status. Blood plasma can also be used for determining the fetal RhD status if the mother is RhD- as maternal blood plasma contains maternal [[DNA]] and trace amounts of fetal DNA. In early pregnancy, around 3% of the mother’s free-cell DNA is from the fetus, and raises to 6-7% by late pregnancy.<ref name=":1">{{Cite web |last=nonacus-developer |date=2021-06-11 |title=Non-Invasive Fetal RhesusD Blood Genotyping |url=https://nonacus.com/blog-non-invasive-fetal-rhesusd-blood-genotyping/ |access-date=2024-04-07 |website=nonacus |language=en-US}}</ref> Blood samples can be obtained through [[venipuncture]] of the mother. Since plasma and other components of blood have different densities, [[centrifugation]] of blood samples with added [[anticoagulant]] (such as [[Ethylenediaminetetraacetic acid|EDTA]]) can segregate blood contents into multiple layers. Blood plasma can then be isolated from the other components. It can be genotyped using real time PCR to determine the RhD status of the fetus.<ref name=":1" /> The method of extracting fetal DNA from maternal blood plasma is considered to be a type of non-invasive [[prenatal testing]].

=== Non-invasive extraction ===

Non-invasive [[prenatal testing]] can be used if the mother is RhD-<ref>{{Cite journal|last=Saramago|first=Pedro|last2=Yang|first2=Huiqin|last3=Llewellyn|first3=Alexis|last4=Walker|first4=Ruth|last5=Harden|first5=Melissa|last6=Palmer|first6=Stephen|last7=Griffin|first7=Susan|last8=Simmonds|first8=Mark|date=Mar 2018|title=High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation|url=https://www.ncbi.nlm.nih.gov/pubmed/29580376|journal=Health Technology Assessment (Winchester, England)|volume=22|issue=13|pages=1–172|doi=10.3310/hta22130|issn=2046-4924|pmc=PMC5890172|pmid=29580376|via=}}</ref>. However, in the case of maternal RhD status being negative, invasive prenatal testing may be used to determine the foetal RhD status instead. The two most common invasive methods of extracting foetal DNA are [[chorionic villus sampling]] (CVS) and [[amniocentesis]] (AMC)<ref>{{Cite journal|last=Carlson|first=Laura M.|last2=Vora|first2=Neeta L.|date=June 2017|title=Prenatal Diagnosis: Screening and Diagnostic Tools|url=https://www.ncbi.nlm.nih.gov/pubmed/28499534|journal=Obstetrics and Gynecology Clinics of North America|volume=44|issue=2|pages=245–256|doi=10.1016/j.ogc.2017.02.004|issn=1558-0474|pmc=PMC5548328|pmid=28499534|via=}}</ref>. These invasive procedures can be conducted on both RhD+ and RhD- mothers. After the invasive procedure, medications that prevent the Rh [[Immunization|immunisation]] are usually prescribed to RhD- mothers<ref>{{Cite journal|last=Crowther|first=C. A.|last2=Keirse|first2=M. J.|date=2000|title=Anti-D administration in pregnancy for preventing rhesus alloimmunisation|url=https://www.ncbi.nlm.nih.gov/pubmed/10796088|journal=The Cochrane Database of Systematic Reviews|issue=2|pages=CD000020|doi=10.1002/14651858.CD000020|issn=1469-493X|pmid=10796088}}</ref>. This is done to avoid the production of maternal anti-D [[Antibody|antibodies]] which may attack the foetal blood cells should the foetus be Rh incompatible with the mother<ref>{{Cite journal|last=Brinc|first=Davor|last2=Lazarus|first2=Alan H.|date=2009|title=Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn|url=https://www.ncbi.nlm.nih.gov/pubmed/20008198|journal=Hematology. American Society of Hematology. Education Program|pages=185–191|doi=10.1182/asheducation-2009.1.185|issn=1520-4383|pmid=20008198}}</ref>.

=== Invasive extraction ===

Non-invasive [[prenatal testing]] can be used if the mother is RhD-. However, in the case of maternal RhD status being positive, invasive prenatal testing may be used to determine the fetal RhD status instead. The two most common invasive methods of extracting fetal DNA are [[chorionic villus sampling]] (CVS) and [[amniocentesis]] (AMC). These invasive procedures can be conducted on both RhD+ and RhD- mothers. After the invasive procedure, medications that prevent the Rh [[immunization]] are usually prescribed to RhD- mothers. This is done to avoid the production of maternal anti-D [[Antibody|antibodies]] which may attack the fetal blood cells should the fetus be Rh incompatible with the mother.

==== Chorionic villus sampling ====

[[Chorionic villus sampling]] is usually doneperformed between the 10th and 13th week of pregnancy,. itIt samples [[chorionic villi]], which are tiny projections of [[Placenta|placental tissue]]<ref>{{Cite journal|last=Alfirevic|first=Z.|last2=Sundberg|first2=K.|last3=Brigham|first3=S.|date=2003|title=Amniocentesis and chorionic villus sampling for prenatal diagnosis|url=https://www.ncbi.nlm.nih.gov/pubmed/12917956|journal=The Cochrane Database of Systematic Reviews|issue=3|pages=CD003252|doi=10.1002/14651858.CD003252|issn=1469-493X|pmc=PMC4171981|pmid=12917956}}</ref>. As the placental tissues are derived from [[Embryonicembryonic cell|embryonic cells]]s, hence, itthey containscontain foetalfetal genetic information that can be used to determine the child’schild's RhD status<ref>{{Cite journal|last=Kickler|first=T. S.|last2=Blakemore|first2=K.|last3=Shirey|first3=R. S.|last4=Nicol|first4=S.|last5=Callan|first5=N.|last6=Ness|first6=P. M.|last7=Escallon|first7=C.|last8=Dover|first8=G.|date=May 1992|title=Chorionic villus sampling for fetal Rh typing: clinical implications|url=https://www.ncbi.nlm.nih.gov/pubmed/1375812|journal=American Journal of Obstetrics and Gynecology|volume=166|issue=5|pages=1407–1411|issn=0002-9378|pmid=1375812|via=}}</ref>. There are two types of chorionic villus sampling. Trans-cervical sampling involves inserting a [[catheter]] through the [[cervix]] into the [[placenta]] to obtain villi,; an [[ultrasound]] is used to guide the catheter to the site of sampling<ref name=":4" />. Trans-abdominal sampling requires the insertion of a needle through the [[abdomen]] and [[uterus]] to obtain placental tissue<ref name=":4" />. [[Local anesthesia|Local anaesthesia]] can be applied to reduce the pain from [[InvasiveMinimally invasive procedure|invasive procedures]]<ref name=":4">{{Cite web|url=https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/chorionic-villus-sampling-cvs|title=Chorionic Villus Sampling (CVS)|website=Johns Hopkins Medicine Health Library|language=en|access-date=2019-04-08}}</ref>.

==== Amniocentesis ====

[[Amniocentesis]] is another invasive procedure which can be used to collect foetalfetal DNA samples.<refsup>{{Cite web|url=https:[<nowiki//www.healthline.com/health/amniocentesis|title=Amniocentesis>[[Wikipedia:Identifying Purpose,reliable Proceduresources and(medicine)|''medical Risks|date=2012-07-18|website=Healthline|language=en|access-date=2019-04-09}}citation needed'']]]</refsup>. This procedure is usually done between the 15th week toand 20th week of [[pregnancy]]<ref name=":3">{{Cite web|url=https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=92&contentid=p07762|title=Amniocentesis - Health Encyclopedia - University of Rochester Medical Center|website=www.urmc.rochester.edu|access-date=2019-04-08}}</ref>. The purpose of AMC is to extract a small amount of [[amniotic fluid]] as foetalfetal cells may be shed from the foetusfetus and are suspended in the amniotic fluid<ref. name=":3"Since />. Thethe foetalfetal genome can be found in these cells. Therefore, extracting amniotic fluid canprovides the required foetalfetal genetic material for the genotyping of the RhD gene<ref>{{Cite journal|last=Cotorruelo|first=C.|last2=Biondi|first2=C.|last3=García Borrás|first3=S.|last4=Di Mónaco|first4=R.|last5=Martino|first5=W.|last6=Racca|first6=A.|date=2001|title=[Rh system genotyping in amniotic fluid]|url=https://www.ncbi.nlm.nih.gov/pubmed/11265629|journal=Medicina|volume=61|issue=1|pages=76–78|issn=0025-7680|pmid=11265629}}</ref>. Before amniocentesis commences, the doctor will inject local anaestheticsanesthetics to the mother's abdomen<ref name=":3" />. The doctor will then applyuse an ultrasound to locate the foetusfetus in the uterus<ref name=":3" />. Under the guidance of the [[ultrasound imaging]], a long, thin, hollow needle will insertbe inserted through the skin of the abdomen to the uterus of the mother<ref name=":3" />. The needle is used to withdraw a trace amount of amniotic fluid<ref name=":3" />. It willis then be removed from the maternal body and the extracted amniotic fluid extracted will beis sent to the laboratory for further testing.

== Genotyping of RhD gene ==

The presence of the RhD gene in an individual’sindividual's genome is determined by [[genotyping]]. Firstly, the body fluid containing an individual’sindividual's DNA will be extracted. DNA will then be isolated from unwanted impurities. The isolated DNA will then be mixed with various reagents to prepare the [[Polymerasepolymerase chain reaction|polymerase chain reactions]]s (PCR) mixture. The PCR mixture usually contains [[Taq polymerase|Taq DNA polymerase]], [[DNA primer|DNA primers]]s, [[Deoxyribonucleotide|deoxyribonucleotidesdeoxyribonucleotide]]s (dNTP) and [[buffer solution]]<ref name=":5">{{Cite journal|last=Lorenz|first=Todd C.|date=2012-05-22|title=Polymerase chain reaction: basic protocol plus troubleshooting and optimization strategies|url=https://www.ncbi.nlm.nih.gov/pubmed/22664923|journal=Journal of Visualized Experiments: JoVE|issue=63|pages=e3998|doi=10.3791/3998|issn=1940-087X|pmc=PMC4846334|pmid=22664923}}</ref>. The DNA primers are specific for [[exon]] 7 and exon 10<ref>{{Cite journal|last=Hromadnikova|first=Ilona|last2=Vechetova|first2=Lenka|last3=Vesela|first3=Klara|last4=Benesova|first4=Blanka|last5=Doucha|first5=Jindrich|last6=Kulovany|first6=Eduard|last7=Vlk|first7=Radovan|date=Jul 2005|title=Non-invasive fetal RHD exon 7 and exon 10 genotyping using real-time PCR testing of fetal DNA in maternal plasma|url=https://www.ncbi.nlm.nih.gov/pubmed/15980640|journal=Fetal Diagnosis and Therapy|volume=20|issue=4|pages=275–280|doi=10.1159/000085085|issn=1015-3837|pmid=15980640|via=}}</ref>. Under different circumstances, primers for other regions of the RhD gene, such as [[intron]] 4 and exon 5, may also be used<ref>{{Cite journal|last=Dovč-Drnovšek|first=Tadeja|last2=Klemenc|first2=Polona|last3=Toplak|first3=Nataša|last4=Blejec|first4=Tanja|last5=Bricl|first5=Irena|last6=Rožman|first6=Primož|date=Feb 2013|title=Reliable Determination of Fetal RhD Status by RHD Genotyping from Maternal Plasma|url=https://www.ncbi.nlm.nih.gov/pubmed/23637648|journal=Transfusion Medicine and Hemotherapy: Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|volume=40|issue=1|pages=37–43|doi=10.1159/000345682|issn=1660-3796|pmc=PMC3636019|pmid=23637648|via=}}</ref>. The mixture will be subjected to a series of PCR which is performed by a [[thermal cycler]]<ref name=":5" />. By the end of the PCR process, the amount of RhD gene will be amplified if it is present. The product of the PCR will be analysedanalyzed by [[gel electrophoresis]]. Before gel electrophoresis, [[Molecular-weight size marker|DNA reference ladder]], a [[Positive control group|positive control]] containing DNA with RhD gene, and the PCR product will be loaded onto the wells of the gel<ref name=":5" />. An [[Electric current|electricalelectric current]] will be applied and the DNA fragments will migrate to the positive terminal as they are negative in charge. Since DNA fragments have different molecular sizes, the larger they are, the slower they migrate<ref name=":6">{{Cite journal|last=Lee|first=Pei Yun|last2=Costumbrado|first2=John|last3=Hsu|first3=Chih-Yuan|last4=Kim|first4=Yong Hoon|date=2012-04-20|title=Agarose gel electrophoresis for the separation of DNA fragments|url=https://www.ncbi.nlm.nih.gov/pubmed/22546956|journal=Journal of Visualized Experiments: JoVE|issue=62|doi=10.3791/3923|issn=1940-087X|pmc=PMC4846332|pmid=22546956}}</ref>. UtilisingUtilizing this property, DNA fragments with different molecular masses can be segregated. With the help of gel staining and visualisingvisualizing devices such as [[Transillumination|UV trans-illuminators]], RhD gene DNA fragments, if present, will be visible as a band with its corresponding molecular mass<ref name=":6" />. Further DNA sequencing can be conducted to confirm that the sequence of product DNA fragments matches that of the RhD gene sequence.

== Clinical Applications ==

{{Citation needed span|text=Rh factor testing is crucial to the prevention ofprevent haemolytic conditions caused by the Rh incompatibility.{{Citation needed|date=AprilMay 2019|reason=Needs reference to sources.2024}} The consequence of having haemolytic conditions can be dangerous or even lethal as it may lead to multiple complications<ref>{{Cite journal|last=Nadgeriev|first=M. K.|last2=Amelina|first2=O. P.|date=Jan 1966|title=[Complications in the transfusion of RH-incompatible blood]|url=https://www.ncbi.nlm.nih.gov/pubmed/4964445|journal=Sovetskaia Meditsina|volume=29|issue=1|pages=95–97|issn=0038-5077|pmid=4964445|via=}}</ref>. Not only does Rh factor testing determine the rhesus status of the individuals, but also indicate the necessity for further medical intervention.

=== Prevention of Rh group incompatibility in blood transfusion ===

When RhD antigens on red blood cells are exposed to an individual with RhD- status, high-frequency of [[Immunoglobulin G|IgG]] [[Rho(D) immune globulin|anti-RhD]] [[Antibody|antibodies]] will be developed in the RhD- individual’sindividual's body<ref name=":7">{{Cite book|url=https://www.ncbi.nlm.nih.gov/books/NBK2269/|title=The Rh blood group|last=Dean|first=Laura|date=2005|publisher=National Center for Biotechnology Information (US)|language=en}}</ref>. The antibodies then attack red blood cells with attached RhD [[Antigen|antigensantigen]]s and lead to the destruction of these cells. This condition is known as a [[Hemolytic reaction|haemolytic reaction]].<ref name=":8">{{Cite journal|last=Strobel|first=Erwin|date=2008|title=Hemolytic Transfusion Reactions|url=https://www.ncbi.nlm.nih.gov/pubmed/21512623|journal=Transfusion Medicine and Hemotherapy: Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|volume=35|issue=5|pages=346–353|doi=10.1159/000154811|issn=1660-3796|pmc=PMC3076326|pmid=21512623}}</ref> The destruction of red blood cells releases [[Hemoglobin|haemoglobinhemoglobin]] to the bloodstream. HaemoglobinHemoglobin may be excreted through [[urine]], causing [[Hemoglobinuria|haemoglobinuria]]<ref name=":8" />. The sudden release of haemoglobinhemoglobin will also pass through the liver and be metabolisedmetabolized into [[bilirubin]], which in high concentrations, accumulates under the skin to cause [[jaundice]]<ref name=":8" />. Liberation of blood cell debris into the circulation will also cause [[disseminated intravascular coagulation]]<ref>{{Citation|last=Costello|first=Ryan A.|title=Disseminated Intravascular Coagulation (DIC)|date=2019|url=http://www.ncbi.nlm.nih.gov/books/NBK441834/|work=StatPearls|publisher=StatPearls Publishing|pmid=28722864|access-date=2019-04-09|last2=Nehring|first2=Sara M.}}</ref>.

==== Symptoms of Rh group incompatibility in blood donation ====

Patients receiving incompatible [[blood transfusion]] may have pale skin, [[splenomegaly]], [[hepatomegaly]] and the yellowing of mouth and eyes. In addition, their urine may appear in dark colourcolor and the patients may experience dizziness and confusion<ref name=":9">{{Cite web|url=https://www.hopkinsmedicine.org/health/conditions-and-diseases/hemolytic-anemia|title=Hemolytic Anemia|website=Johns Hopkins Medicine Health Library|language=en|access-date=2019-04-09}}</ref>. [[Tachycardia]], the increase in heart rate, is also a symptom of the haemolytic disease<ref name=":9" />.

=== Prevention of haemolytic disease of the newborn ===

In the case of pregnancy, when an RhD- mother carries an RhD+ fetus, some of the fetal red blood cells may cross the placenta into the maternal circulation, sensitisingsensitizing the mother to produce anti-RhD antibodies<ref name=":7" />. Since the mixing of fetal and maternal blood occurs mainly during separation of the placenta during delivery, the first RhD+ pregnancy rarely causes any danger to the foetusfetus as delivery occurs before the synthesis of antibodies by the mother<ref name=":7" />. However, if the mother were to conceive another RhD+ child in the future, the anti-RhD antibodies will cross the placenta to attack and lyse the red cells of the foetusfetus, causing the aforementioned haemolytic reaction in the foetusfetus known as [[Hemolytic disease of the newborn|haemolytic disease of the newborn]]<ref name=":7" />. This disease is usually fatal for the foetusfetus and hence preventive measures are conducted.

==== Symptoms of haemolytic disease of the newborn ====

Symptoms of the disease may vary in each pregnancy. They are usually not noticeable during pregnancy. However, prenatal tests may reveal yellow colouring of amniotic fluid, which is caused by the buildup of bilirubin.<ref name=":10">{{Cite web|url=https://www.urmc.rochester.edu/encyclopedia/content.aspx?ContentTypeID=90&ContentID=P02368|title=Hemolytic Disease of the Newborn (HDN) - Health Encyclopedia - University of Rochester Medical Center|website=www.urmc.rochester.edu|access-date=2019-04-09}}</ref>. Splenomegaly, [[cardiomegaly]] and hepatomegaly may occur in the baby.<ref name=":10" />. Excessive [[tissue fluid]] may accumulate in the [[stomach]], [[Lung|lungslung]]s or [[scalp]]. These are typically signs of [[hydrops fetalis]].<ref name=":10" />.

After birth, the symptoms of the child are similar to that of incompatible blood transfusion in adults.  The baby may have pale skin due to [[Anemia|anaemia]]. The yellowing of the [[umbilical cord]], skin and eyes, also known as jaundice, may arise within 24 to 36 hours of birth.<ref name=":10" />. Signs of hydrops fetalis such as the enlargement of [[spleen]], [[heart]] and [[liver]], along with severe [[edema]], will continue after birth.<ref name=":10" />.

=== Medical Intervention ===

Normally, no extra medical intervention is required when maternal Rh status is RhD+, nor RhD- mothers going through first pregnancy. However, in the case of a sensitisedsensitized RhD- mother (previously conceived an RhD+ child) and the foetusfetus being Rh+, medication such as an [[Rho(D) immune globulin|anti-D immunoglobulin]], called RhoGAM, will be given to the RhD- mother<ref>{{Cite journal|last=Kumpel|first=B. M.|date=Jul 1997|title=Monoclonal anti-D for prophylaxis of RhD haemolytic disease of the newborn|url=https://www.ncbi.nlm.nih.gov/pubmed/9269715|journal=Transfusion Clinique Et Biologique: Journal De La Societe Francaise De Transfusion Sanguine|volume=4|issue=4|pages=351–356|issn=1246-7820|pmid=9269715|via=}}</ref>. Injecting RhD- mother with anti-D immunoglobulinRhoGAM has been proven effective in avoiding the sensitisation of RhD+ antigen, even though the mechanism of how this medication works remains obscure<ref>{{Cite journal|last=Brinc|first=Davor|last2=Lazarus|first2=Alan H.|date=2009|title=Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn|url=https://www.ncbi.nlm.nih.gov/pubmed/20008198|journal=Hematology. American Society of Hematology. Education Program|pages=185–191|doi=10.1182/asheducation-2009.1.185|issn=1520-4383|pmid=20008198}}</ref>. Anti-D immunoglobulin injection is also offered to RhD- individuals who have been mistakenly transfused with RhD+ blood<ref>{{Cite journal|last=Asfour|first=M.|last2=Narvios|first2=Aida|last3=Lichtiger|first3=Benjamin|date=2004-07-13|title=Transfusion of RhD-Incompatible Blood Components in RhD-Negative Blood Marrow Transplant Recipients|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1435608/|journal=Medscape General Medicine|volume=6|issue=3|pages=|issn=1531-0132|pmc=PMC1435608|pmid=15520646|via=}}</ref>.

This injection is given to the RhD- mother during the second trimester when there is incompatibility between her and the father. Another injection is given a couple days after delivery if the baby is found to be RhD+.  These injections may also be given to RhD- mothers after a miscarriage/abortion, after injury to the abdomen, or after the prenatal tests mentioned before of amniocentesis and chorionic villus sampling (cite1).   Anti-D immunoglobulin injection is also offered to RhD- individuals who have been mistakenly transfused with RhD+ blood.

== References ==

{{Reflist}}

[[Category:Blood]]

[[Category:Birth control]]